Key Insights

Highlights

Success Rate

86% trial completion

Published Results

16 trials with published results (16%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

6.0%

6 terminated out of 100 trials

Success Rate

85.7%

-0.8% vs benchmark

Late-Stage Pipeline

5%

5 trials in Phase 3/4

Results Transparency

44%

16 of 36 completed with results

Key Signals

16 with results86% success

Data Visualizations

Phase Distribution

80Total
Not Applicable (21)
Early P 1 (3)
P 1 (23)
P 2 (28)
P 3 (4)
P 4 (1)

Trial Status

Completed36
Recruiting20
Active Not Recruiting17
Unknown9
Not Yet Recruiting6
Terminated6

Trial Success Rate

85.7%

Benchmark: 86.5%

Based on 36 completed trials

Clinical Trials (100)

Showing 20 of 20 trials
NCT05256225Phase 3RecruitingPrimary

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

NCT07738315Phase 2Not Yet RecruitingPrimary

Elemene Liposomes in Endometrial Cancer

NCT01366144Phase 1Active Not Recruiting

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

NCT02465060Phase 2Active Not Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT07285044Phase 2Recruiting

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

NCT05714553Phase 1Terminated

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

NCT07723235Not ApplicableNot Yet Recruiting

Web-based Lifestyle Program, mHealth and EMA Intervention, to Improve Weight Loss in Rural Stage I-III Postmenopausal Breast and Endometrial Cancer Survivors, HERO-C Trial

NCT05919264Phase 1Recruiting

FOG-001 in Locally Advanced or Metastatic Solid Tumors

NCT04567771Not ApplicableActive Not Recruiting

Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer

NCT05078047Phase 3Active Not Recruiting

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

NCT07527143RecruitingPrimary

Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer

NCT05691010Early Phase 1Recruiting

A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer

NCT07662824Not ApplicableNot Yet Recruiting

Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy

NCT07279571RecruitingPrimary

GYN-AIDE: Gynecologic Oncology Navigation Through AI-Driven Education

NCT04251416Phase 2Active Not RecruitingPrimary

A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

NCT06365905RecruitingPrimary

Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding

NCT05316467Phase 2TerminatedPrimary

Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma

NCT03671811Phase 2Active Not Recruiting

Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy

NCT06102252Not ApplicableCompletedPrimary

Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as Aneo Adjuvant Treatment in Advanced Endometrial Carcinoma

NCT04634617Active Not RecruitingPrimary

Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer Survivors

Scroll to load more

Research Network

Activity Timeline